Ranbaxy settles dispute with Takeda Pharma
Takeda has granted Ranbaxy a non-exclusive royalty free license for its US patents covering Actos, Ranbaxy, which is majority owned by Daiichi Sankyo.
Ranbaxy Laboratories has settled litigation with Japan's Takeda Pharmaceutical over a generic equivalent version of anti-diabetic drug Actos. Takeda has granted Ranbaxy a non-exclusive royalty free license for its US patents covering Actos, Ranbaxy, which is majority owned by Daiichi Sankyo, said in a statement on Monday.